Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) have earned an average rating of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.60.
Several equities analysts have recently commented on CLSD shares. Needham & Company LLC raised Clearside Biomedical from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Thursday, November 10th. StockNews.com initiated coverage on Clearside Biomedical in a report on Friday, November 4th. They issued a “hold” rating on the stock. Stifel Nicolaus upgraded Clearside Biomedical from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Wednesday, November 9th. Finally, HC Wainwright boosted their price objective on Clearside Biomedical from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, November 10th.
Insider Activity at Clearside Biomedical
In related news, Director Nancy J. Hutson purchased 30,000 shares of the business’s stock in a transaction on Thursday, November 17th. The shares were bought at an average price of $1.33 per share, for a total transaction of $39,900.00. Following the acquisition, the director now directly owns 83,000 shares in the company, valued at $110,390. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Nancy J. Hutson purchased 30,000 shares of the business’s stock in a transaction on Thursday, November 17th. The shares were bought at an average price of $1.33 per share, for a total transaction of $39,900.00. Following the acquisition, the director now directly owns 83,000 shares in the company, valued at $110,390. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George M. Lasezkay sold 20,030 shares of the company’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $1.46, for a total value of $29,243.80. Following the sale, the chief executive officer now owns 484,577 shares in the company, valued at approximately $707,482.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,930 shares of company stock worth $73,943. 12.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Clearside Biomedical
Clearside Biomedical Stock Up 2.0 %
Shares of Clearside Biomedical stock opened at $1.50 on Monday. Clearside Biomedical has a 52 week low of $0.98 and a 52 week high of $2.85. The business’s fifty day simple moving average is $1.27 and its 200-day simple moving average is $1.35. The firm has a market cap of $90.29 million, a PE ratio of -18.75 and a beta of 1.83.
Clearside Biomedical (NASDAQ:CLSD – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). Clearside Biomedical had a negative net margin of 17.15% and a negative return on equity of 16.13%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $16.50 million. As a group, equities analysts expect that Clearside Biomedical will post -0.52 earnings per share for the current year.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F.
- Get a free copy of the StockNews.com research report on Clearside Biomedical (CLSD)
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.